These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 21549509)
1. Naloxone-induced cortisol predicts mu opioid receptor binding potential in specific brain regions of healthy subjects. Wand GS; Weerts EM; Kuwabara H; Frost JJ; Xu X; McCaul ME Psychoneuroendocrinology; 2011 Nov; 36(10):1453-9. PubMed ID: 21549509 [TBL] [Abstract][Full Text] [Related]
2. The relationship between naloxone-induced cortisol and delta opioid receptor availability in mesolimbic structures is disrupted in alcohol-dependent subjects. Wand GS; Weerts EM; Kuwabara H; Wong DF; Xu X; McCaul ME Addict Biol; 2013 Jan; 18(1):181-92. PubMed ID: 22264217 [TBL] [Abstract][Full Text] [Related]
3. The relationship between naloxone-induced cortisol and mu opioid receptor availability in mesolimbic structures is disrupted in alcohol dependent subjects. Wand GS; Weerts EM; Kuwabara H; Wong DF; Xu X; McCaul ME Alcohol; 2012 Sep; 46(6):511-7. PubMed ID: 22717196 [TBL] [Abstract][Full Text] [Related]
4. A comparison of the naloxone test with ovine CRH and insulin hypoglycaemia in the evaluation of the hypothalamic-pituitary-adrenal axis in normal man. Inder WJ; Ellis MJ; Evans MJ; Donald RA Clin Endocrinol (Oxf); 1995 Oct; 43(4):425-31. PubMed ID: 7586616 [TBL] [Abstract][Full Text] [Related]
5. Positron emission tomography imaging of mu- and delta-opioid receptor binding in alcohol-dependent and healthy control subjects. Weerts EM; Wand GS; Kuwabara H; Munro CA; Dannals RF; Hilton J; Frost JJ; McCaul ME Alcohol Clin Exp Res; 2011 Dec; 35(12):2162-73. PubMed ID: 21689118 [TBL] [Abstract][Full Text] [Related]
6. The effects of alcoholism on the hypothalamic-pituitary-adrenal axis: interaction with endogenous opioid peptides. Inder WJ; Joyce PR; Ellis MJ; Evans MJ; Livesey JH; Donald RA Clin Endocrinol (Oxf); 1995 Sep; 43(3):283-90. PubMed ID: 7586596 [TBL] [Abstract][Full Text] [Related]
7. The mu-opioid receptor polymorphism A118G predicts cortisol responses to naloxone and stress. Chong RY; Oswald L; Yang X; Uhart M; Lin PI; Wand GS Neuropsychopharmacology; 2006 Jan; 31(1):204-11. PubMed ID: 16123758 [TBL] [Abstract][Full Text] [Related]
8. Catechol-O-methyltransferase polymorphism alters hypothalamic-pituitary-adrenal axis responses to naloxone: a preliminary report. Oswald LM; McCaul M; Choi L; Yang X; Wand GS Biol Psychiatry; 2004 Jan; 55(1):102-5. PubMed ID: 14706432 [TBL] [Abstract][Full Text] [Related]
9. Acute HPA axis response to naltrexone differs in female vs. male smokers. Roche DJ; Childs E; Epstein AM; King AC Psychoneuroendocrinology; 2010 May; 35(4):596-606. PubMed ID: 19837518 [TBL] [Abstract][Full Text] [Related]
10. Endogenous opioid tone in patients with rheumatoid arthritis. Kassimos D; Choy EH; Grossman AB; Chikanza IC; Panayi GS Br J Rheumatol; 1996 May; 35(5):436-40. PubMed ID: 8646433 [TBL] [Abstract][Full Text] [Related]
11. Aspirin increases the human hypothalamic-pituitary-adrenal axis response to naloxone stimulation. Hockings GI; Grice JE; Crosbie GV; Walters MM; Jackson AJ; Jackson RV J Clin Endocrinol Metab; 1993 Aug; 77(2):404-8. PubMed ID: 8393884 [TBL] [Abstract][Full Text] [Related]
12. The role of endogenous opioids in neurohypophysial and hypothalamo-pituitary-adrenal axis hormone secretory responses to stress in pregnant rats. Douglas AJ; Johnstone HA; Wigger A; Landgraf R; Russell JA; Neumann ID J Endocrinol; 1998 Aug; 158(2):285-93. PubMed ID: 9771473 [TBL] [Abstract][Full Text] [Related]
13. Population-specific effects of the Asn40Asp polymorphism at the mu-opioid receptor gene (OPRM1) on HPA-axis activation. Hernandez-Avila CA; Covault J; Wand G; Zhang H; Gelernter J; Kranzler HR Pharmacogenet Genomics; 2007 Dec; 17(12):1031-8. PubMed ID: 18004207 [TBL] [Abstract][Full Text] [Related]
14. The effect of naloxone on adrenocorticotropin and cortisol release: evidence for a reduced response in depression. Burnett FE; Scott LV; Weaver MG; Medbak SH; Dinan TG J Affect Disord; 1999 Jun; 53(3):263-8. PubMed ID: 10404712 [TBL] [Abstract][Full Text] [Related]
15. Naloxone-mediated activation of the hypothalamic-pituitary-adrenal axis in chronic fatigue syndrome. Scott LV; Burnett F; Medbak S; Dinan TG Psychol Med; 1998 Mar; 28(2):285-93. PubMed ID: 9572086 [TBL] [Abstract][Full Text] [Related]
16. Evidence of a disturbance of the hypothalamic-pituitary-adrenal axis in polycystic ovary syndrome: effect of naloxone. Lanzone A; Guido M; Ciampelli M; Fulghesu AM; Pavone V; Proto C; Caruso A; Mancuso S Clin Endocrinol (Oxf); 1996 Jul; 45(1):73-7. PubMed ID: 8796141 [TBL] [Abstract][Full Text] [Related]
17. Nalmefene causes greater hypothalamic-pituitary-adrenal axis activation than naloxone in normal volunteers: implications for the treatment of alcoholism. Schluger JH; Ho A; Borg L; Porter M; Maniar S; Gunduz M; Perret G; King A; Kreek MJ Alcohol Clin Exp Res; 1998 Oct; 22(7):1430-6. PubMed ID: 9802524 [TBL] [Abstract][Full Text] [Related]
18. The Impact of the Opioid Antagonist Naloxone on Experimentally Induced Craving in Nicotine-Dependent Individuals. Krause D; Warnecke M; Schuetz CG; Soyka M; Manz KM; Proebstl L; Kamp F; Chrobok AI; Pogarell O; Koller G Eur Addict Res; 2018; 24(5):255-265. PubMed ID: 30423575 [TBL] [Abstract][Full Text] [Related]
19. Effect of opioid receptor antagonists on hypothalamic-pituitary-adrenal activity in rhesus monkeys. Williams KL; Ko MC; Rice KC; Woods JH Psychoneuroendocrinology; 2003 May; 28(4):513-28. PubMed ID: 12689609 [TBL] [Abstract][Full Text] [Related]